Sofia Necander

538 total citations · 2 hit papers
18 papers, 334 citations indexed

About

Sofia Necander is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Physiology. According to data from OpenAlex, Sofia Necander has authored 18 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Rheumatology and 6 papers in Physiology. Recurrent topics in Sofia Necander's work include Eosinophilic Disorders and Syndromes (7 papers), Asthma and respiratory diseases (6 papers) and Eosinophilic Esophagitis (5 papers). Sofia Necander is often cited by papers focused on Eosinophilic Disorders and Syndromes (7 papers), Asthma and respiratory diseases (6 papers) and Eosinophilic Esophagitis (5 papers). Sofia Necander collaborates with scholars based in Sweden, United Kingdom and United States. Sofia Necander's co-authors include Maria Jison, Enrico Heffler, Claire Emson, Claus Bachert, Philippe Gevaert, Vivian H. Shih, Martin Y. Desrosiers, Ubaldo J. Martin, James L. Kreindler and Jody Tversky and has published in prestigious journals such as New England Journal of Medicine, American Journal of Respiratory and Critical Care Medicine and Journal of Allergy and Clinical Immunology.

In The Last Decade

Sofia Necander

14 papers receiving 329 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial

2021 205 citations Claus Bachert, Joseph K. Han et al. Journal of Allergy and Clinical Immunology profile →
Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

2024 69 citations Michael E. Wechsler, Parameswaran Nair et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sofia Necander Sweden	6	193	150	140	131	71	18	334
Lutaf Islam United States	5	350 1.8×	425 2.8×	401 2.9×	95 0.7×	153 2.2×	10	577
Giuseppe Valenti Italy	11	246 1.3×	100 0.7×	23 0.2×	188 1.4×	48 0.7×	17	288
Giulia Pelaia Italy	9	162 0.8×	62 0.4×	11 0.1×	108 0.8×	43 0.6×	20	240
VJ Lund Australia	4	220 1.1×	243 1.6×	52 0.4×	93 0.7×	100 1.4×	5	360
Cindy K. Cook United States	10	403 2.1×	427 2.8×	37 0.3×	108 0.8×	31 0.4×	11	461
Nicola LaVigne Canada	7	195 1.0×	46 0.3×	4 0.0×	132 1.0×	61 0.9×	13	255
Panteha Eshtiaghi Canada	5	86 0.4×	164 1.1×	4 0.0×	15 0.1×	46 0.6×	10	356
María Angeles Zambonino Spain	7	155 0.8×	150 1.0×	4 0.0×	49 0.4×	29 0.4×	12	355
Warner Carr United States	8	91 0.5×	36 0.2×	2 0.0×	69 0.5×	16 0.2×	21	145
Hiromi Tadaki Japan	12	89 0.5×	49 0.3×	2 0.0×	107 0.8×	45 0.6×	26	262

Countries citing papers authored by Sofia Necander

Since Specialization

Citations

This map shows the geographic impact of Sofia Necander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sofia Necander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sofia Necander more than expected).

Fields of papers citing papers by Sofia Necander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sofia Necander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sofia Necander. The network helps show where Sofia Necander may publish in the future.

Co-authorship network of co-authors of Sofia Necander

This figure shows the co-authorship network connecting the top 25 collaborators of Sofia Necander. A scholar is included among the top collaborators of Sofia Necander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sofia Necander. Sofia Necander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Hellmich, Bernhard, Arnaud Bourdin, David Jayne, et al.. (2025). The Effect of Benralizumab and Mepolizumab on Use of Oral Glucocorticoids in Patients With Eosinophilic Granulomatosis With Polyangiitis. Arthritis & Rheumatology. 78(3). 695–704.

Merkel, Peter A., Parameswaran Nair, Nader Khalidi, et al.. (2025). Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Annals of the Rheumatic Diseases. 84(11). 1888–1899. 2 indexed citations

Wechsler, Michael E., Parameswaran Nair, Nader Khalidi, et al.. (2025). Two-Year Efficacy and Safety of Benralizumab for the Treatment of Eosinophilic Granulomatosis with Polyangiitis. Journal of Allergy and Clinical Immunology. 155(2). AB430–AB430. 1 indexed citations

Agmon‐Levin, Nancy, David Jayne, Christian Pagnoux, et al.. (2025). Discontinuation of Oral Glucocorticoids and Achievement of Remission in Patients With Eosinophilic Granulomatosis With Polyangiitis Treated With Benralizumab or Mepolizumab. ACR Open Rheumatology. 7(9). e70096–e70096.

Wechsler, Michael E., Parameswaran Nair, Benjamin Terrier, et al.. (2024). Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine. 390(10). 911–921. 69 indexed citations breakdown →

Mukherjee, Manali, Chynna Huang, Brian Kim, et al.. (2024). Late Breaking Abstract - Benralizumab reduces eosinophils and ANCA in sputum in EGPA. PA5372–PA5372. 1 indexed citations

Wechsler, Michael E., Parameswaran Nair, Benjamin Terrier, et al.. (2024). Efficacy and Safety of Benralizumab Compared with Mepolizumab in the Treatment of Eosinophilic Granulomatosis with Polyangiitis in Patients Receiving Standard of Care Therapy: Phase 3 MANDARA Study. Journal of Allergy and Clinical Immunology. 153(2). AB364–AB364. 2 indexed citations

Bourdin, Arnaud, et al.. (2024). Asthma remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) following treatment with benralizumab or mepolizumab. PA5364–PA5364.

Rodríguez‐Suárez, Eva, Michael E. Wechsler, Peter A. Merkel, et al.. (2024). Effect of treatment with benralizumab or mepolizumab on the serum proteome in eosinophilic granulomatosis with polyangiitis. PA828–PA828. 1 indexed citations

10.

Pagnoux, Christian, et al.. (2024). POS0858 HOW SYMPTOMS AND TREATMENTS IMPACT THE EXPERIENCES OF PATIENTS WITH EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS PARTICIPATING IN A CLINICAL TRIAL. Annals of the Rheumatic Diseases. 83. 1071–1072.

11.

Weidolf, Lars, Sofia Necander, Elwin Verheij, et al.. (2022). Characterization of Clinical Absorption, Distribution, Metabolism, and Excretion and Pharmacokinetics of Velsecorat Using an Intravenous Microtracer Combined with an Inhaled Dose in Healthy Subjects. Drug Metabolism and Disposition. 50(2). 150–157. 4 indexed citations

12.

Karlsson, Niklas, et al.. (2022). Physical activity end-points in trials of chronic respiratory diseases: summary of evidence. ERJ Open Research. 8(1). 541–2021. 6 indexed citations

13.

Singh, Dave, Jutta Beier, Carol Astbury, et al.. (2021). The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD. European Respiratory Journal. 59(4). 2100972–2100972. 11 indexed citations

14.

Bachert, Claus, Joseph K. Han, Martin Y. Desrosiers, et al.. (2021). Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology. 149(4). 1309–1317.e12. 205 indexed citations breakdown →

15.

Chupp, Geoffrey, K.M. Beeh, Alexandra Jauhiainen, et al.. (2021). Results of a Phase 2b Dose Finding Study of Velsecorat, an Inhaled Non-Steroidal, Selective Glucocorticoid Receptor Modulator in Asthma (GRANIT). A1202–A1202. 1 indexed citations

16.

Sadiq, Muhammad Waqas, Sara Asimus, Maria G. Belvisi, et al.. (2021). Characterisation of pharmacokinetics, safety and tolerability in a first‐in‐human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease. British Journal of Clinical Pharmacology. 88(1). 260–270. 12 indexed citations

17.

Psallidas, Ioannis, Vibeke Backer, Piotr Kuna, et al.. (2020). A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma. American Journal of Respiratory and Critical Care Medicine. 203(3). 296–306. 17 indexed citations

18.

Asimus, Sara, Jukka Mäenpää, Rainard Fuhr, et al.. (2020). Safety, Tolerability and Pharmacokinetics (PK) of AZD8154, A Selective PI3Kγδ Inhibitor, After Single and Multiple Ascending Inhaled Doses in Healthy Volunteers. A3022–A3022. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact